Sequel twiist AID System to Integrate with Senseonics Eversense 365 One-Year CGM

What You Should Know: 

– Sequel Med Tech, LLC, known for its innovative insulin delivery technology, and Senseonics Holdings, Inc., developer of long-term implantable continuous glucose monitoring (CGM) systems, announced a significant commercial development agreement. 

– The collaboration will integrate Sequel’s twiist Automated Insulin Delivery (AID) System, powered by Tidepool, with Senseonics’ Eversense® 365 CGM system.

This partnership marks a notable advancement in diabetes management, as the twiist AID System is set to become the first automated insulin delivery system compatible with the Senseonics Eversense 365. The Eversense 365 stands out as the world’s only CGM system featuring a sensor designed to last for a full year, offering unprecedented longevity for users. The integration aims to provide people living with type 1 diabetes a new level of flexibility and personalization in managing their condition.

This agreement expands the choices available to users of the twiist system. Once integrated, individuals with type 1 diabetes using twiist will have the flexibility to select between two compatible CGM partners: the Senseonics Eversense 365 or Abbott’s FreeStyle Libre 3 Plus sensor, allowing them to choose the option that best suits their individual needs.

FDA Clearance

The path for this integration was paved in September 2024 when the Eversense 365 received FDA clearance as an integrated continuous glucose monitoring (iCGM) system, specifically allowing its use within AID systems. Driven by a shared commitment to simplifying diabetes management, Senseonics and Sequel have already commenced the integration work.

The twiist AID System itself, cleared for use in individuals aged six and older with type 1 diabetes, features unique technology that directly measures the volume of insulin delivered with each micro-dose. Its algorithm, based on the community-driven Tidepool Loop, automatically adjusts basal insulin delivery using real-time CGM data and predictive glucose levels. The twiist system is expected to be commercially available in the second quarter of 2025.

Availability

The integrated Eversense 365 and twiist system is anticipated to be available to users in the third quarter of 2025, marking a significant milestone in offering more personalized and convenient diabetes management solutions.

What You Should Know: 

– Sequel Med Tech, LLC, known for its innovative insulin delivery technology, and Senseonics Holdings, Inc., developer of long-term implantable continuous glucose monitoring (CGM) systems, announced a significant commercial development agreement. 

– The collaboration will integrate Sequel’s twiist Automated Insulin Delivery (AID) System, powered by Tidepool, with Senseonics’ Eversense® 365 CGM system.

This partnership marks a notable advancement in diabetes management, as the twiist AID System is set to become the first automated insulin delivery system compatible with the Senseonics Eversense 365. The Eversense 365 stands out as the world’s only CGM system featuring a sensor designed to last for a full year, offering unprecedented longevity for users. The integration aims to provide people living with type 1 diabetes a new level of flexibility and personalization in managing their condition.

This agreement expands the choices available to users of the twiist system. Once integrated, individuals with type 1 diabetes using twiist will have the flexibility to select between two compatible CGM partners: the Senseonics Eversense 365 or Abbott’s FreeStyle Libre 3 Plus sensor, allowing them to choose the option that best suits their individual needs.

FDA Clearance

The path for this integration was paved in September 2024 when the Eversense 365 received FDA clearance as an integrated continuous glucose monitoring (iCGM) system, specifically allowing its use within AID systems. Driven by a shared commitment to simplifying diabetes management, Senseonics and Sequel have already commenced the integration work.

The twiist AID System itself, cleared for use in individuals aged six and older with type 1 diabetes, features unique technology that directly measures the volume of insulin delivered with each micro-dose. Its algorithm, based on the community-driven Tidepool Loop, automatically adjusts basal insulin delivery using real-time CGM data and predictive glucose levels. The twiist system is expected to be commercially available in the second quarter of 2025.

Availability

The integrated Eversense 365 and twiist system is anticipated to be available to users in the third quarter of 2025, marking a significant milestone in offering more personalized and convenient diabetes management solutions.